Patient Access

April 25, 2024 Our Commitment to Patients Means Never Stop Evolving - Our Patient Access Philosophy Tolga Tanguler, Alnylam's Chief Commercial Officer discusses Alnylam's Patient Access Philosophy and approach to access Read More ›
May 9, 2022 Building a Collaborative Framework for Facilitating Patient Access to Innovative Therapies Alnylam worked with leading European economists and other healthcare experts to develop what we call the Value-Based Negotiation Framework (VBNF) to help... Read More ›
December 21, 2021 Alnylam Publishes 2021 Patient Access Philosophy Report Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may... Read More ›
December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which... Read More ›
December 12, 2019 Building Bridges to Support Patients’ Care Supporting patients and their caregivers by facilitating access to innovative treatments is at the core of our Patient Access Philosophy. Read More ›
September 9, 2019 Alnylam's Patient Access Philosophy - Our Progress Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view... Read More ›
Subscribe to Patient Access

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site